Swiss pharmaceutical company Sandoz has announced plans to launch unbranded versions of weight-loss drugs in the Canadian market starting next year, with discounts of up to 70% compared to branded counterparts, coinciding with the expiration of patents.
In an interview with the Financial Times, Richard Saynor, CEO of Sandoz, emphasized that this move aims to improve patient access to effective weight management treatments while also reducing healthcare system costs. The entry of generic drugs into the obesity treatment market is expected to significantly lower prices and expand treatment options.
